Strong antibody reactivity to HIV-1 synthetic peptides in seropositive indigenous Warao people

Isabel Durango , Sandra Losada , Henry Bermúdez , Julián Villalba , Yoneira Sulbaran, Rossana C. Jaspe , Jacobus H. de Waard , Héctor R. Rangel , Óscar O. Noya, Flor H. Pujol, .

Keywords: HIV-1, peptides, antibodies, indigenous people, receptors, CXCR4, Venezuela

Abstract

Introduction. Previous studies have described an epidemic of HIV-1 in the indigenous Warao population living in the Orinoco Delta, Venezuela. The Warao face extraordinary challenges amid of their ongoing HIV-1 epidemic, the highest reported HIV-1 prevalence in indigenous groups (9.6%) in South America.
Objective. To investigate the antibody reactivity to HIV-1 synthetic peptides in seropositive individuals, with a particular focus on the indigenous Warao population from Venezuela.
Materials and methods. The HIV-1 Pol region from infected patients’ isolates was amplified, sequenced, and analyzed using phylogenetic tools. Custom-designed synthetic peptides were derived from conserved regions of HIV-1 glycoproteins 41 and 120, based on reference sequences. Multiple antigen blot assays were used to evaluate the presence of antibodies against synthetic peptides.
Results. The most frequent HIV-1 subtype was B, the most common in Venezuela, although some individuals were infected with subtype A1. Distinct patterns of reactivity to synthetic peptides were observed between the sera of the general population and the Warao population; the sera of the latter exhibited a high intensity of peptide recognition.
Conclusions. The use of synthetic peptides, coupled with the robust performance of multiple antigen blot assays, enriches our understanding of antibody responses in different HIV-1-infected populations.

Downloads

Download data is not yet available.
  • Isabel Durango Laboratorio de Virología Molecular, Centro de Microbiología y Biología Celular, Instituto Venezolano de Investigaciones Científicas, Caracas, Venezuela https://orcid.org/0009-0006-4405-9452
  • Sandra Losada Sección de Biohelmintiasis, Instituto de Medicina Tropical, Facultad de Medicina, Universidad Central de Venezuela, Caracas, Venezuela https://orcid.org/0009-0007-9574-6954
  • Henry Bermúdez Sección de Biohelmintiasis, Instituto de Medicina Tropical, Facultad de Medicina, Universidad Central de Venezuela, Caracas, Venezuela https://orcid.org/0000-0002-4679-0218
  • Julián Villalba Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA https://orcid.org/0000-0001-9230-8747
  • Yoneira Sulbaran Laboratorio de Virología Molecular, Centro de Microbiología y Biología Celular, Instituto Venezolano de Investigaciones Científicas, Caracas, Venezuela https://orcid.org/0000-0002-3170-353X
  • Rossana C. Jaspe Laboratorio de Virología Molecular, Centro de Microbiología y Biología Celular, Instituto Venezolano de Investigaciones Científicas, Caracas, Venezuela https://orcid.org/0000-0002-4816-1378
  • Jacobus H. de Waard Departamento de Tuberculosis, Servicio Autónomo Instituto de Biomedicina "Dr. Jacinto Convit", Universidad Central de Venezuela, Caracas, Venezuela https://orcid.org/0000-0003-4118-1015
  • Héctor R. Rangel Laboratorio de Virología Molecular, Centro de Microbiología y Biología Celular, Instituto Venezolano de Investigaciones Científicas, Caracas, Venezuela https://orcid.org/0000-0001-5937-9690
  • Óscar O. Noya Sección de Biohelmintiasis, Instituto de Medicina Tropical, Facultad de Medicina, Universidad Central de Venezuela, Caracas, Venezuela https://orcid.org/0000-0003-1575-8159
  • Flor H. Pujol Laboratorio de Virología Molecular, Centro de Microbiología y Biología Celular, Instituto Venezolano de Investigaciones Científicas, Caracas, Venezuela https://orcid.org/0000-0001-6086-6883

References

1. World Health Organization. Global health sector strategy on HIV 2016-2021 towards ending aids. Geneva: WHO; 2016. Accessed on: May 1st, 2024. Available at: http://apps.who.int/iris/bitstream/10665/246178/1/WHO-HIV-2016.05-eng.pdf

2. Russell NK, Nazar K, Del Pino S, Alonso Gonzalez M, Díaz Bermúdez XP, Ravasi G. HIV, syphilis, and viral hepatitis among Latin American indigenous peoples and Afro A systematic review. Rev Panam Salud Pública. 2019;43:e17. https://doi.org/10.26633/RPSP.2019.17

3. Villalba J, Bello G, Maes M, Sulbaran Y, Garzaro D, Loureiro CL, et al. HIV-1 epidemic in Warao Amerindians from Venezuela. AIDS. 2013;27:1783-91. https://doi.org/10.1089/AID.2015.0155

4. Maes M, Verhagen LM, Ortega D, Sánchez GL, Segovia Y, del Nogal B, et al. Influence of bacille Calmette-Guérin on tuberculin skin testing in Venezuelan Amerindians in high tuberculosis burden areas. J Infect Dev Ctries. 2014;8:176-83. https://doi.org/10.3855/jidc.3297

5. Rangel HR, Bello G, Villalba JA, Sulbaran YF, Garzaro D, Maes M, et al. The evolving HIV-1 epidemic in Warao Amerindians is dominated by an extremely high frequency of CXCR4-utilizing strains. AIDS Res Hum Retroviruses. 2015;31:1265-8. https://doi.org/10.1089/AID.2015.0155

6. Yandrapally S, Mohareer K, Arekuti G, Vadankula GR, Banerjee S. HIV co-receptortropism: Cellular and molecular events behind the enigmatic co-receptor switching. Crit Rev Microbiol. 2021;47:499-516. https://doi.org/10.1080/1040841X.2021.1902941

7. Cretich M, Gori A, D’Annessa I, Chiari M, Colombo G. Peptides for infectious diseases: From probe design to diagnostic microarrays. Antibodies (Basel). 2019;8:23. https://doi.org/10.3390/antib8010023

8. Chico M, Sandoval C, Guevara A, Calvopiña M, Cooper PJ, Reed SG, et al. Chagas disease in Ecuador: Evidence for disease transmission in an indigenous population in the Amazon region. Mem Inst Oswaldo Cruz. 1997;92:317-20. https://doi.org/10.1590/s0074-02761997000300002

9. Gabbai AA, Bordin JO, Vieira-Filho JP, Kuroda A, Oliveira AS, Cruz MV, et al. Selectivity of human T lymphotropic virus type-1 (HTLV-1) and HTLV-2 infection among different populations in Brazil. Am J Trop Med Hyg. 1993;49:664-71. https://doi.org/10.4269/ajtmh.1993.49.664

10. Araújo Z, de Waard JH, Camargo M, López-Ramos JE, de Larrea CF, Vanegas M, et al. Diagnostic potential of the serological response to synthetic peptides from Mycobacterium tuberculosis antigens for discrimination between active and latent tuberculosis infections. Int J Pept Res Ther. 2022;28:98. https://doi.org/10.1007/s10989-022-10392-3

11. Alcaro MC, Peroni E, Rovero P, Papini AM. Synthetic peptides in the diagnosis of HIV infection. Curr Protein Pept Sci. 2003;4:285-90. https://doi.org/10.2174/1389203033487117

12. Borras-Cuesta F, Fedon Y, Petit-Camurdan A. Enhancement of peptide immunogenicity by linear polymerization. Eur J Immunol. 1988;18:199-202. https://doi.org/10.1002/eji.1830180203

13. Rangel HR, Garzaro D, Gutiérrez CR, Vásquez L, Guillen G, Torres JR, Pujol FH. HIV diversity in Venezuela: Predominance of HIV type 1 subtype B and genomic characterization of non-B variants. AIDS Res Hum Retroviruses. 2009;25:347-50. https://doi.org/10.1089/aid.2008.0241

14. Noya O, Alarcon de Noya B. The multiple antigen blot assay (MABA): A simple immunoenzymatic technique for simultaneous screening of multiple antigens. Immunol. Letters. 1998;63:53-6. https://doi.org/10.1016/s0165-2478(98)00055-8

15. Gauna A, Losada S, Lorenzo M, Toledo M, Bermúdez H, D’Angelo P, et al. Use of synthetic peptides and multiple antigen blot assay in the immunodiagnosis of hepatitis C virus infection. Viral Immunol. 2018;31:568-74. https://doi.org/10.1089/vim.2018.0023

16. Dean AG, Arner TG, Sunki GG, Friedman R, Lantinga M, Sangam S, et al. Epi Info™, a database and statistics program for public health professionals. Atlanta: CDC; 2011.

17. Liang Y, Lin H, Dzakah EE, Tang S. Influence of combination antiretroviral therapy on HIV-1 serological responses and their implications: A systematic review and meta-analysis. Front Immunol. 2022;13:844023. https://doi.org/10.3389/fimmu.2022.844023

18. Rangel HR, Garzaro D, Rodríguez AK, Ramírez AH, Ameli G, Del Rosario Gutiérrez C, et al. Deletion, insertion, and stop codon mutations in Vif genes of HIV-1 infecting slow progressor patients. J Infect Dev Ctries. 2009;3:531-8. https://doi.org/10.3855/jidc.471 19. Wang B. Viral factors in non-progression. Front Immunol. 2013;4:355. https://doi.org/10.3389/fimmu.2013.00355

20. Zaunders J, van Bockel D. Innate and adaptive immunity in long-term non-progression in HIV disease. Front Immunol. 2013;4:95. https://doi.org/10.3389/fimmu.2013.00095

21. Araújo Z, Palacios A, Biomon R, Rivas-Santiago B, Serrano CJ, Enciso-Moreno L, et al. Concordance between IFN-γ gene +874 A/T polymorphism and interferon-γ expression in a TB-endemic indigenous setting. Rev Soc Bras Med Trop. 2017;50:199-207. https://doi.org/10.1590/0037-8682-0398-2016

22. Araújo Z, Camargo M, Moreno Pérez DA, Wide A, Pacheco D, Díaz Arévalo D, et al. Differential NRAMP1 gene’s D543N genotype frequency: Increased risk of contracting tuberculosis among Venezuelan populations. Hum Immunol. 2023;84:484-91. https://doi.org/10.1016/j.humimm.2023.06.003

23. Verhagen LM, Hermsen M, Rivera-Olivero I, Sisco MC, Pinelli E, Hermans PW, et al. Stunting correlates with high salivary and serum antibody levels after 13-valent pneumococcal conjugate vaccination of Venezuelan Amerindian children. Vaccine. 2016;34:2312-20. https://doi.org/10.1016/j.vaccine.2016.03.066

How to Cite
1.
Durango I, Losada S, Bermúdez H, Villalba J, Sulbaran Y, Jaspe RC, et al. Strong antibody reactivity to HIV-1 synthetic peptides in seropositive indigenous Warao people. Biomed. [Internet]. 2025 May 30 [cited 2026 Mar. 2];45(2):267-76. Available from: https://revistabiomedicaorg.biteca.online/index.php/biomedica/article/view/7510

Some similar items:

Published
2025-05-30
Section
Original articles

Altmetric

Article metrics
Abstract views
Galley vies
PDF Views
HTML views
Other views
Escanea para compartir
QR Code